Biomaterials as novel penetration enhancers for transdermal and dermal drug delivery systems

Drug Delivery

Volumn 20, Issue 5, 2013, Pages 199-209

  Chen, Yang ^a   Wang, Manli ^a,b   Fang, Liang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b BEIHUA UNIVERSITY   (China)

Author keywords

Biomaterial; Dermal; Mechanism; Penetration enhancer; Transdermal

Indexed keywords

ALPHA CYCLODEXTRIN; BENZALKONIUM CHLORIDE; BETA CYCLODEXTRIN; BIOMATERIAL; BOTULINUM TOXIN A; CERAMIDE; CETYLPYRIDINIUM SALT; CHITOSAN DERIVATIVE; CHOLESTEROL; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN A; DENDRIMER; FATTY ACID; FLUOROURACIL; GAMMA CYCLODEXTRIN; GLYCINE LYSINE HISTIDING; GRANISETRON; LIPOPROTEIN; LIPOSOME; N TRIMETHYL CHITOSAN; NON CONJUGATED PEPTIDE; OLIGODIMETHYLSILOXANE DERIVATIVE; PENETRATION ENHANCING AGENT; POLYAMIDOAMINE; PROTEIN TRANSDUCTION DOMAIN; SKIN LIPID; SYNTHETIC PEPTIDE; T2 PEPTIDE; TD 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DERMATITIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; HUMAN; LIPID BILAYER; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN ABSORPTION; SKIN PENETRATION; SKIN PERMEABILITY; STATIC ELECTRICITY; STRATUM CORNEUM; THERAPY EFFECT; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; BIOCOMPATIBLE MATERIALS; CELL-PENETRATING PEPTIDES; CHITOSAN; CYCLODEXTRINS; DENDRIMERS; DIMETHYLPOLYSILOXANES; DRUG DELIVERY SYSTEMS; HUMANS; MAGAININS; OLIGOPEPTIDES; SKIN; SKIN ABSORPTION;

EID: 84879559419     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.801533     Document Type: Review

References (113)

1. Akimoto T, Aoyagi T, Minoshima J, Nagase Y. (1997). Polymeric percutaneous drug penetration enhancer: synthesis and enhancing property of PEG/PDMS block copolymer with a cationic end group. J Control Release 49:229-41. (Pubitemid 28020276)
2. Akimoto T, Kawahara K, Nagase Y, Aoyagi T. (2000). Preparation of oligodimethylsiloxanes with sugar moiety at a terminal group as a transdermal penetration enhancer. Macromol Chem Phys 201: 2729-34.
3. Akimoto T, Kawahara K, Nagase Y, Aoyagi T. (2001). Polymeric transdermal drug penetration enhancer: the enhancing effect of oligodimethylsiloxane containing a glucopyranosyl end group. J Control Release 77:49-57. (Pubitemid 33022615)
4. Akimoto T, Nagase Y. (2003). Novel transdermal drug penetration enhancer: synthesis and enhancing effect of alkyldisiloxane compounds containing glucopyranosyl group. J Control Release 88:243-52. (Pubitemid 36287341)
5. Aoyagi T, Akimoto T, Nagase Y. (1992a). Novel silicones for transdermal therapeutic system, IV. Modified route to prepare oligodimethylsiloxane containing cationic end-group and its property as transdermal penetration enhancer. Makromo Chem 193:2821-8.
6. Aoyagi T, Nakamura T, Yabuchi Y, Nagase Y. (1992b). Novel silicones for transdermal therapeutic system III: Preparation of pyridinio or ammonio-terminated polydimethylsiloxanes and the evaluation as transdermal penetration enhancer. Polymer 24:545-53. (Pubitemid 23577108)
7. Aoyagi T, Tadenuma R, Nagase Y. (1996). Novel silicones for transdermal therapeutic system, 6. Preparation of oligodimethylsiloxane containing 2-pyrrolidone moiety as a terminal group and its enhancing effect on transdermal drug penetration. Macromol Chem Phys 197:677-86. (Pubitemid 126464766)
8. Aoyagi T, Takamura K, Nagase Y. (1992c). Novel silicones for transdermal therapeutic system. II. Preparation of oligodimethylsiloxanes containing diethyl phosphoramidate group at the chain end and the the evaluation as transdermal penetration enhancer. Polymer J 24: 375-81.
9. Aoyagi T, Takamura Y, Nakamura T, et al. (1992d). Novel silicones for transdermal therapeutic systems: 1. Synthesis of 1-methyl-4-pyridinio-terminated polydimethylsiloxane and evaluation as a transdermal penetration enhancer. Polymer 33:2203-7.
10. Aoyagi T, Terashima O, Nagase Y, Matsui K. (1991). Preparation of a polymer containing hexadecylpyridinium bromide groups and its utilization as a transdermal drug penetration enhancer. Polymer 32: 2106-11. (Pubitemid 21713845)
11. Aoyagi T, Terashima O, Suzuki N, et al. (1990). Polymerization of benzalkonium chloride-type monomer and application to percutaneous drug absorption enhancer. J Control Release 13:63-71. (Pubitemid 20221202)
12. Arima H, Miyaji T, Irie T, et al. (1996). Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by betacyclodextrin derivatives in hydrophilic ointment. Chem Pharm Bull 44:582-6.
13. Babita K, Rana V, Tiwary AK. (2005). Lipid synthesis inhibitors: effect on epidermal lipid conformational changes and percutaneous permeation of levodopa. AAPS PharmSciTech 6:E473-81.
14. Babita K, Tiwary AK. (2004a). Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa. Curr Drug Deliv 1:397-403.
15. Babita K, Tiwary AK. (2004b). Transcutaneous delivery of levodopa: enhancement by fatty acid synthesis inhibition. Mol Pharm 2: 57-63. (Pubitemid 40314730)
16. Babita SG, Tiwary AK. (2002). Role of sphingosine synthesis inhibition in transcutaneous delivery of levodopa. Int J Pharm 238:43-50. (Pubitemid 34457874)
17. Bason MM, Gordon V, Maibach HI. (1991). Skin Irritation. Int J Dermatol 30:623-6.
18. Berardesca E, Distante F. (1994). The modulation of skin irritation. Contact Dermatitis 31:281-7. (Pubitemid 24361100)
19. Borowska K, Laskowska B, Magoń A, et al. (2010). PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion of the guest. Int J Pharm 398:185-9.
20. Borowska K, Wołowiec S, Rubaj A, et al. (2012). Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene-in vivo study. Int J Pharm 426:280-3.
21. Bos JD, Meinardi MM. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9: 165-9. (Pubitemid 30255378)
22. Brown MB. (2006). Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 13:175-87.
23. Carmichael NM, Dostrovsky JO, Charlton MP. (2010). Peptidemediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 149: 316-24.
24. Chauhan AS, Sridevi S, Chalasani KB, et al. (2003). Dendrimermediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 90:335-43. (Pubitemid 36869009)
25. Chen Y, Shen Y, Guo X, et al. (2006). Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 24:455-60.
26. Cheng Y, Man N, Xu T, et al. (2007). Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 96:595-602.
27. Davaran S, Hanaee J, Rashidi MR, et al. (2006). Influence of poly (ethylene glycol)-g-cyclodextrin complexes on stabilization and transdermal permeation of ascorbic acid. J Biomed Mater Res A 78: 590-4. (Pubitemid 44253543)
28. de Jager MW, Gooris GS, Dolbnya IP, et al. (2004). Modelling the stratum corneum lipid organisation with synthetic lipid mixtures: the importance of synthetic ceramide composition. BBA-Biomembranes 1684:132-40. (Pubitemid 39140986)
29. Di Colo G, Burgalassi S, Zambito Y. (2004). Effects of different N-trimethyl chitosans on in vitro/in vivo ofloxacin transcorneal permeation. J Pharm Sci 93:2851-62. (Pubitemid 39506634)
30. Duncan R, Izzo L. (2005). Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57:2215-37. (Pubitemid 41759394)
31. Elias PM, Tsai J, Menon GK, et al. (2002). The potential of metabolic interventions to enhance transdermal drug delivery. J Investig Dermatol Symp Proc 7:79-85. (Pubitemid 36151099)
32. Fawell S, Seery J, Daikh Y, et al. (1994). TAT-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91:664-8. (Pubitemid 24041462)
33. Feingold KR. (2007). Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res 48:2531-46. (Pubitemid 350272838)
34. Feingold KR. (2009). The outer frontier: the importance of lipid metabolism in the skin. J Lipid Res 50:s417-22.
35. Filipowicz A, Wołowiec S. (2011). Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers. Int J Pharm 408:152-6.
36. Finnin BC, Morgan TM. (1999). Transdermal penetration enhancers: applications, limitations, and potential. J Pharm Sci 88:955-8. (Pubitemid 29480582)
37. Giuseppina S, Silvia R, Maria CB, et al. (2005). Buccal penetration enhancement properties of N-trimethyl chitosan: influence of quaternization degree on absorption of a high molecular weight molecule. Int J Pharm 297:146-55.
38. Gonçalves E, Kitas E, Seelig J. (2005). Binding of oligoarginine to membrane lipids and heparan sulfate: structural and thermodynamic characterization of a cell-penetrating peptide. Biochemstry 44: 2692-702. (Pubitemid 40279574)
39. Guillard EC, Tfayli A, Laugel C, Baillet-Guffroy A. (2009). Molecular interactions of penetration enhancers within ceramides organization: A FTIR approach. Eur J Pharm Sci 36:192-9.
40. Gupta M, Mahajan A, Babita K, et al. (2004). Inhibition of skin sphingosine synthesis: enhanced percutaneous permeation of 5-fluorouracil. Pharmzie 59:212-6. (Pubitemid 38391427)
41. Hadgraft J. (2004). Skin deep. Eur J Pharm Biopharm 58:291-9. (Pubitemid 39037236)
42. He W, Guo X, Xiao L, Feng M. (2009). Study on the mechanisms of chitosan and its derivatives used as transdermal penetration enhancers. Int J Pharm 382:234-43.
43. He W, Guo X, Zhang M. (2008). Transdermal permeation enhancement of N-trimethyl chitosan for testosterone. Int J Pharm 356:82-7.
44. Ho A, Schwarze SR, Mermelstein SJ, et al. (2001). Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61:474-7. (Pubitemid 32128600)
45. Hou YW, Chan MH, Hsu HR, et al. (2007). Transdermal delivery of proteins mediated by non-covalently associated arginine-rich intracellular delivery peptides. Exp Dermatol 16:999-1006.
46. Hsu T, Mitragotri S. (2011). Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci USA 108:15816-21.
47. Jonker C, Hamman JH, Kotzé AF. (2002). Intestinal paracellular permeation enhancement with quaternized chitosan: in situ and in vitro evaluation. Int J Pharm 238:205-13. (Pubitemid 34457889)
48. Karande P, Jain A, Ergun K, et al. (2005). Design principles of chemical penetration enhancers for transdermal drug delivery. Proc Natl Acad Sci USA 102:4688-93. (Pubitemid 40471515)
49. Karande P, Mitragotri S. (2009). Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim Biophysica Acta 1788:2362-73.
50. Kaushik S, Krishnan A, Prausnitz MR, Ludovice PJ. (2001). Magaininmediated disruption of stratum corneum lipid vesicles. Pharm Res 18: 894-6. (Pubitemid 32783529)
51. Kim YC, Late S, Banga AK, et al. (2008). Biochemical enhancement of transdermal delivery with magainin peptide: modification of electrostatic interactions by changing pH. Int J Pharm 362:20-8.
52. Kim YC, Ludovice PJ, Prausnitz MR. (2007). Transdermal delivery enhanced by magainin pore-forming peptide. J Control Release 122: 375-83. (Pubitemid 47404674)
53. Kotzé AF, Luessen HL, Kotzé HL, de Leeuw BJ, et al. (1997). Ntrimethyl chitosan chloride as a potential absorption enhancer across mucosal surface: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res 14:1197-202. (Pubitemid 27432543)
54. Küchler S, Radowski MR, Blaschke T, et al. (2009). Nanoparticles for skin penetration enhancement-a comparison of a dendritic coremultishell- nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 71:243-50.
55. Kumar S, Sahdev P, Perumal O, Tummala H. (2012). Identification of a novel skin penetration enhancement peptide by phage display peptide library screening. Mol Pharm 9:1320-30.
56. Legendre JY, Rault I, Petit A, et al. (1995). Effects of b-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur J Pharm Sci 3:311-22.
57. Li Y, Quan Y, Zang L, et al. (2009). Trypsin as a novel potential absorption enhancer for improving the transdermal delivery of macromolecules. J Pharm Pharmacol 61:1005-12.
58. Li Y, Quan Y, Zang L, et al. (2008). Transdermal delivery of insulin using trypsin as a biochemical enhancer. Biol Pharm Bull 31: 1574-9.
59. Lim JM, Chang MY, Park SG, et al. (2003). Penetration enhancement in mouse skin and lipolysis in adipocytes by TAT-GKH, a new cosmetic ingredient. J Cosmet Sci 54:483-91. (Pubitemid 37524294)
60. Loftsson T, Masson M. (2001). Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 225:15-30. (Pubitemid 32728196)
61. Loftsson T, Olafsson JH. (1998). Cyclodextrins: new drug delivery systems in dermatology. Int J Dermatol 37:241-6. (Pubitemid 28189682)
62. Loftsson T, Sigurdardóttir AM, ólafsson JH. (1995). Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation. Int J Pharm 115:255-8.
63. Loftsson T, Sigurdardóttir AM. (1997). Cyclodextrins as skin penetration enhancers. In: Szejtli J, Szente L, eds. Proceedings of the eighth international symposium on cyclodextrins. Dordrecht, Netherlands: Kluwer Academic Publishers, 403-6.
64. Lopes L B, Brophy CM, Furnish E, et al. (2005). Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Pharm Res 22:750-7. (Pubitemid 40768587)
65. Lopez RFV, Collett JH, Bentley MV. (2000). Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone. Int J Pharm 200:127-32. (Pubitemid 30177258)
66. Lv H, Zhang Z, Wang X, et al. (2011). A biomimetic chitosan derivates: preparation, characterization and transdermal enhancement studies of N-arginine chitosan. Molecules 16:6778-90.
67. Matsuda H, Arima H. (1999). Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliver Rev 36:81-99. (Pubitemid 29074478)
68. Matsuzaki K, Nakamura A, Murase O, et al. (1997). Modulation of magainin 2-lipid bilayer interactions by peptide charge. Biochemistry 36:2104-11. (Pubitemid 27104701)
69. Menon GK, Ghadially R, Williams ML, Elias PM. (1992). Lamellar bodies as delivery systems of hydrolytic enzymes: implications for normal and abnormal desquamation. Br J Dermatol 126: 337-45.
70. Menon GK. (2002). New insights into skin structure: scratching the surface. Adv Drug Deliver Rev 54:S3-17.
71. Mignani S, Kazzouli SE, Bousmina M, Majoral JP. (2013). Expand classical drug administration ways by emerging routes using dendrimers drug delivery systems: a concise overview. Adv Drug Deliv Rev http://dx.doi.org/10.1016/j. addr.2013.01.001.
72. Nagase Y, Aoyagi T, Akimoto T, Fuchikami T. (1992). Novel silicones for transdermal therapeutic system, V. A novel method of preparation of carboxy-terminated polydimethylsiloxane and its enhancing effect on transdermal drug penetration. Makromol Chem 13:441-6.
73. Naik A, Kalia YN, Guy RH. (2000). Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technol Today 3:318-26.
74. Nanjwade BK, Bechra HM, Derkar GK, et al. (2009). Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 38: 185-96.
75. Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. (2012). Cellpenetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des 80:639-46.
76. Ohtake K, Maeno T, Ueda H, et al. (2003). Poly-L-arginine predominantly increases the paracelullar permeability of hydrophilic macromolecules across rabbit nasal epithelium in vitro. Pharm Res 20: 153-60. (Pubitemid 36269721)
77. Orienti I, Zecchi V, Bertasi V, Fini A. (1991). Release of ketoprofen from dermal bases in presence of endrimersns: effect of the affinity constant determined in semisolid vehicles. Arch Pharm 324:943-7.
78. Pathan IB, Setty CM. (2009). Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res 8:173-9.
79. Patil S, Singh P, Szolar-Platzer C, Maibach H. (1996). Epidermal enzymes as penetration enhancers in transdermal drug delivery? J Pharm Sci 85:249-52. (Pubitemid 26082466)
80. Prausnitz MR, Langer R. (2008). Transdermal drug delivery. Nat Biotechnol 26:1261-8.
81. Rothbard JB, Garlington S, Lin Q, et al. (2000). Conjugation of arginine oligomers to endrimersn A facilitates topical delivery and inhibition of inflammation. Nat Med 6:1253-7.
82. Sakuma S, Suita M, Masaoka Y, et al. (2010). Oligoarginine-linked polymers as a new class of penetration enhancers. J Control Release 148:187-96.
83. Sapra B, Jain S, Tiwary AK. (2008). Transdermal delivery of carvedilol containing glycyrrhizin and chitosan as permeation enhancers: biochemical, biophysical, microscopic and pharmacodynamic evaluation. Drug Deliv 15:443-54.
84. Schwarze SR, Dowdy SF. (2000). In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21:45-8. (Pubitemid 30100337)
85. Shaker DS, Ghanem AH, Li SK, et al. (2003). Mechanistic studies of the effect of hydroxypropyl-b-cyclodextrin on in vitro transdermal permeation of corticosterone through hairless mouse skin. Int J Pharm 253:1-11. (Pubitemid 36197826)
86. Sinha VR, Kaur MP. (2000). Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 26:1131-40.
87. Sinico C, Fadda AM. (2006). Vesicular carriers for dermal drug delivery. Exp Opin Drug Deliv 6:813-25.
88. Sun M, Fan A, Wang Z, Zhao Y. (2012). Dendrimer-mediated drug delivery to the skin. Soft Matter 8:4301-5.
89. Tanner T, Marks R. (2008). Delivering drugs by the transdermal route: review and comment. Skin Res Technol 14:249-60.
90. Taveira SF, Nomizo A, Lopez RFV. (2009). Effect of the iontophoresis of a chitosan gel on doxorubicin skin penetration and cytotoxicity. J Control Release 134:35-40.
91. Thanou M, Verhoef JC, Junginger HE. (2001). Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 50:S91-101.
92. Thanou MM, Kotzé AF, Scharringhausen T, et al. (2000). Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal Caco-2 cell monolayers. J Control Release 64:15-25. (Pubitemid 30035304)
93. Thomas BJ, Finnin BC. (2004). The transdermal revolution. Drug Discov Today 9:697-703. (Pubitemid 39070282)
94. Tsai JC, Guy RH, Thornfeldt CR, et al. (1996). Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci 85:643-8. (Pubitemid 26179655)
95. Uchida T, Kanazawa T, Takashima Y, Okada H. (2011). Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002. Chem Pharm Bull 59: 196-201.
96. Umemura M, Ueda H, Tomono K, Nagai T. (1990). Effect of diethylbeta-cyclodextrin on the release of nitroglycerin from formulations. Drug Des Deliv 6:297-310. (Pubitemid 20349927)
97. Ventura CA, Tommasini S, Falcone A, et al. (2006). Influence of modified endrimersns on solubility and percutaneous absorption of celecoxib through human skin. Int J Pharm 314:37-45.
98. Venuganti VV, Sahdev P, Hildreth M, et al. (2011). Structure-skin permeability relationship of dendrimers. Pharm Res 28:2246-60.
99. Venuganti VVK, Perumal OP. (2008). Effect of poly(amidoamine) (PAMAM) endrimers on skin permeation of 5-fluorouracil. Int J Pharm 361:230-8.
100. Venuganti VVK, Perumal OP. (2009). Poly(amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation, and concentration. J Pharm Sci 98:2345-56.
101. Vives E. (2003). Cellular uptake of the Tat peptide: an endocytosis mechanism following ionic interactions. J Mol Recognit 16: 265-71. (Pubitemid 37231695)
102. Walker RB, Smith EW. (1996). The role of percutaneous penetration enhancers. Adv Drug Deliver Rev 18:295-301. (Pubitemid 26063305)
103. Wang Z, Itoh Y, Hosaka Y, et al. (2003a). Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine endrimers. J Biosci Bioeng 95:541-3. (Pubitemid 36688182)
104. Wang Z, Itoh Y, Hosaka Y, et al. (2003b). Mechanism of enhancement effect of endrimers on transdermal drug permeation through polyhydroxyalkanoate matrix. J Biosci Bioeng 96: 537-40. (Pubitemid 38091228)
105. Welss T, Basketter DA, Schröder KR. (2004). In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol In Vitro 18:231-43. (Pubitemid 38376355)
106. Wertz PW, van den Beergh B. (1998). The physical, chemical and functional properties of lipids in the skin and other biological barriers. Chem Phys Lipids 91:85-96. (Pubitemid 28142956)
107. Williams AC, Barry BW. (2004). Penetration enhancers. Adv Drug Deliver Rev 56:603-18. (Pubitemid 38326936)
108. Yang Y, Sunoqrot S, Stowell C, et al. (2012). Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromolecules 13: 2154-62.
109. Zaro J, Shen WC. (2003). Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem Biophys Res Commun 307:241-7. (Pubitemid 36818860)
110. Zasloff M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin-isolation, characterization of two active forms, and partial c-DNA sequence of a precursor. Proc Natl Acad Sci USA 84: 5449-53. (Pubitemid 17129018)
111. Zesch A. (1983). Skin irritation by topical drugs. Derm Beruf Umwelt 31:74-8. (Pubitemid 13044510)
112. Zhou X, Liu D, Liu H, et al. (2010). Effect of low molecular weight chitosans on drug permeation through mouse skin: 1. Transdermal delivery of baicalin. J Pharm Sci 99:2991-8.
113. Zi P, Yang X, Kuang H, et al. (2008). Effect of HPbCD on solubility and transdermal delivery of capsaicin through rat skin. Int J Pharm 358: 151-8.